Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.

2019-08

Sasadeusz, Joe

Grigg, Andrew P

Hughes, Peter D

Lee Lim, Seng

Lucas, Michaela

McColl, Geoff

McLachlan, Sue Anne

Peters, Marion G

Shackel, Nicholas

Slavin, Monica

Sundararajan, Vijaya

Thompson, Alexander

Doyle, Joseph

Rickard, James

De Cruz, Peter

Gish, Robert G

Visvanathan, Kumar

Anti-CD20

Direct-acting antivirals

Hepatitis B

Inflammatory bowel diseases

Reactivation

Rheumatoid arthritis

Journal Article

10.1016/j.cld.2019.04.012

Because of the relatively high prevalence of both hepatitis B infection and various forms of autoimmune inflammatory diseases treated with aggressive immunotherapy, reactivation of hepatitis B occurs in a substantial number of patients. The risk of reactivation depends on the degree and duration of immunosuppression. A large number of drug treatments have resulted in reactivation of hepatitis B virus infection and, based on the mechanisms and extent of immunosuppression, recommendations for some of the newer classes of immunosuppressive drugs are provided.

link

Clinics in liver disease 2019; 23(3): 521-534

Clinics in liver disease